Granulomatosis with polyangiitis is a multiorgan autoimmune disease with multifaceted clinical manifestations which, due to its rarity and the absence of distinctive clinical features, poses serious diagnostic challenges [2]. Diagnostic criteria for GPA consist of clinical evidence of disease in at least two of three areas (upper airways, lung, and kidney) and biopsy results showing disease at least once [7]. Some recent case reports introduced a possible relationship between coronaviruses and autoimmune disease. Zamani et al. reported a case that demonstrated a possible relationship between coronaviruses and systemic lupus erythematosus (SLE), and she suggested there are no published data on the association of coronaviruses with SLE, but several studies have linked coronaviruses with another autoimmune disease such as multiple sclerosis (MS) and rheumatoid arthritis (RA) [8]. Wegener’s granulomatosis or GPA is also an autoimmune disease where the pathogenesis of it is complex but consists of inflammatory cytokines [9]. Increased interleukin-17 (IL-17), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) levels lead to the formation of inflammatory granulomatous lesions in GPA [10]. Recent studies have shown that hyperactivation of immune cells in patients with COVID-19 leads to elevated levels of various autoantibodies and inflammatory cytokines including IFN-γ and TNF-α [11]. While there have been several reported cases of COVID-19 occurring in patients receiving immunosuppressant treatment for GPA [12, 13], in this study, we report new onset of Wegener’s granulomatosis with unusual manifestations in an aged woman 2 months after COVID-19 infection. Our patient did not have any history of autoimmune disease in her own or her family. After COVID-19 symptom’s recovery, she presented sudden unilateral visual and hearing loss accompanied by peripheral facial palsy and rhinosinusitis symptoms with clinical and radiological evidence of necrosis of the nasal septum, central tympanic membrane perforation, and there was no BC in pure tone audiometry test on the right side. Based on our experiences during the COVID-19 pandemic, in the encounter of an aged woman with a history of COVID-19 and glucocorticoid usage in the treatment of these sudden and rapidly progressive signs and symptoms aforementioned, primarily, we suspected mucormycosis. Eventually, the diagnosis of GPA was established via histopathological findings. Several studies have reported an increase in mucormycosis cases during the COVID-19 pandemic. COVID-19 and glucocorticoid usage as a basic treatment can lead to immune suppression in these patients and lead to the proliferation of opportunistic infections, including mucormycosis [14]. Mucormycosis is a rare but invasive, rapidly progressive, and life-threatening infection. A definite diagnosis of mucormycosis is only confirmed by histological findings. Early diagnosis of mucormycosis is so important given that a delay of diagnosis from 6 to 30 days can increase the mortality from 35 to 66% [15]. The most common clinical manifestation of mucormycosis is the involvement of the paranasal sinuses (39%), followed by the lung (24%), skin (19%), brain (9%), gastrointestinal tract (7%), and a disseminated type (6%), which is similar to GPA, in variety of manifestations, whereas the onset of symptoms in GPA is often more gradual [16]. COVID-19 and GPA share many clinical and radiological presentations. On chest CT, prominent findings in a GPA patient may be ground-glass appearance, consolidation, or even cavitation [12]. These findings may be mutual in a patient with COVID-19-superimposed pneumonia [17]. In our case, subpleural consolidation in the inferior lobe of the left lung was reported due to past COVID-19 pneumonia effects in radiological findings. Therefore, this evidence and normal oxygen saturation in our patient lead to the mass of the lung being an insignificant feature for the evolution of the correct identification. The diagnosis of GPA is often overlooked and delayed due to a wide range of clinical presentations. It is extremely rare to develop GPA after a COVID-19 infection. Jalalzadeh et al. reported ANCA-associated glomerulonephritis in a patient with systemic sclerosis after COVID-19 infection [18]. Bressler et al. reported a case of new-onset GPA with many skin manifestations in the setting of active COVID-19 infection [19]. Selvaraj et al. reported a 60-year-old woman who, 1 month after the COVID-19 infection, presented with persistent fatigue, shortness of breath, and anemia with worsening renal functions, found to have elevated C-ANCA and anti-proteinase 3 (PR3) antibodies, and was diagnosed with GPA [20]. But there is no published data about the new onset of Wegener’s granulomatosis with similar manifestations of our case after COVID-19 infection that has led to the development of serious diagnostic challenges for us.